Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125422481 | 12542248 | 1 | I | 20000405 | 20160628 | 20160708 | 20160708 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-055352 | BRISTOL MYERS SQUIBB | 48.00 | YR | M | Y | 0.00000 | 20160708 | MD | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125422481 | 12542248 | 1 | PS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 600 MG, QD | 382000 | MG | Y | 20972 | 600 | MG | CAPSULE | QD | |||
125422481 | 12542248 | 2 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 600 MG, QD | 382000 | MG | Y | 20972 | 600 | MG | CAPSULE | QD | |||
125422481 | 12542248 | 3 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 400 MG, QD | 382000 | MG | Y | 20972 | 400 | MG | CAPSULE | QD | |||
125422481 | 12542248 | 4 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 400 MG, QD | 382000 | MG | Y | 20972 | 400 | MG | CAPSULE | QD | |||
125422481 | 12542248 | 5 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 600 MG, QD | 382000 | MG | Y | 20972 | 600 | MG | CAPSULE | QD | |||
125422481 | 12542248 | 6 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 600 MG, QD | 382000 | MG | Y | 20972 | 600 | MG | CAPSULE | QD | |||
125422481 | 12542248 | 7 | SS | VIDEX EC | DIDANOSINE | 1 | Oral | 250 MG, QD | Y | 0 | 250 | MG | GASTRO-RESISTANT CAPSULE, HARD | QD | |||||
125422481 | 12542248 | 8 | SS | ZERIT | STAVUDINE | 1 | Oral | 60 MG, QD | Y | 0 | 60 | MG | CAPSULE, HARD | QD | |||||
125422481 | 12542248 | 9 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 6 DF, QD | 2426 | DF | Y | 0 | 6 | DF | QD | ||||
125422481 | 12542248 | 10 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 2 DF, QD | 2426 | DF | Y | 0 | 2 | DF | QD | ||||
125422481 | 12542248 | 11 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 2.5 DF, QD | 2426 | DF | Y | 0 | 2.5 | DF | QD | ||||
125422481 | 12542248 | 12 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 3 DF, QD | 2426 | DF | Y | 0 | 3 | DF | QD | ||||
125422481 | 12542248 | 13 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 5 DF, QD | 2426 | DF | Y | 0 | 5 | DF | QD | ||||
125422481 | 12542248 | 14 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 6 DF, QD | 2426 | DF | Y | 0 | 6 | DF | QD | ||||
125422481 | 12542248 | 15 | SS | ZIAGEN | ABACAVIR SULFATE | 1 | Oral | 600 MG, QD | 256800 | MG | Y | 0 | 600 | MG | QD | ||||
125422481 | 12542248 | 16 | SS | PROZEI | AMPRENAVIR | 1 | Oral | 1800 MG, QD | 770400 | MG | Y | 0 | 1800 | MG | QD | ||||
125422481 | 12542248 | 17 | SS | INTELENCE | ETRAVIRINE | 1 | Oral | 400 MG, QD | 0 | 400 | MG | QD | |||||||
125422481 | 12542248 | 18 | SS | TIVICAY | DOLUTEGRAVIR SODIUM | 1 | Oral | 100 MG, QD | 0 | 100 | MG | QD | |||||||
125422481 | 12542248 | 19 | SS | NORVIR | RITONAVIR | 1 | Oral | 100 MG, QD | 0 | 100 | MG | QD | |||||||
125422481 | 12542248 | 20 | SS | NORVIR | RITONAVIR | 1 | Oral | 200 MG, QD | 0 | 200 | MG | QD | |||||||
125422481 | 12542248 | 21 | SS | PREZISTA | DARUNAVIR ETHANOLATE | 1 | Oral | 600 MG, QD | 0 | 600 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125422481 | 12542248 | 1 | HIV infection |
125422481 | 12542248 | 7 | HIV infection |
125422481 | 12542248 | 8 | HIV infection |
125422481 | 12542248 | 9 | HIV infection |
125422481 | 12542248 | 15 | HIV infection |
125422481 | 12542248 | 16 | HIV infection |
125422481 | 12542248 | 17 | HIV infection |
125422481 | 12542248 | 18 | HIV infection |
125422481 | 12542248 | 19 | HIV infection |
125422481 | 12542248 | 21 | HIV infection |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125422481 | 12542248 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125422481 | 12542248 | Hyperlipidaemia | |
125422481 | 12542248 | Lipodystrophy acquired | |
125422481 | 12542248 | Liver disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125422481 | 12542248 | 1 | 20000613 | 20010814 | 0 | |
125422481 | 12542248 | 2 | 20000613 | 20010814 | 0 | |
125422481 | 12542248 | 3 | 20030613 | 20040220 | 0 | |
125422481 | 12542248 | 4 | 20030613 | 20040220 | 0 | |
125422481 | 12542248 | 5 | 20040221 | 20050511 | 0 | |
125422481 | 12542248 | 6 | 20040221 | 20050511 | 0 | |
125422481 | 12542248 | 7 | 20010815 | 200208 | 0 | |
125422481 | 12542248 | 8 | 20010815 | 200208 | 0 | |
125422481 | 12542248 | 9 | 20010815 | 200208 | 0 | |
125422481 | 12542248 | 10 | 20021203 | 20021230 | 0 | |
125422481 | 12542248 | 11 | 20021231 | 20030306 | 0 | |
125422481 | 12542248 | 12 | 20030307 | 20030331 | 0 | |
125422481 | 12542248 | 13 | 20030401 | 20030605 | 0 | |
125422481 | 12542248 | 14 | 20030606 | 20050511 | 0 | |
125422481 | 12542248 | 15 | 20000613 | 20010814 | 0 | |
125422481 | 12542248 | 16 | 20000613 | 20010814 | 0 | |
125422481 | 12542248 | 17 | 20140613 | 0 | ||
125422481 | 12542248 | 18 | 20140613 | 0 | ||
125422481 | 12542248 | 19 | 20050511 | 20080821 | 0 | |
125422481 | 12542248 | 20 | 20140613 | 0 | ||
125422481 | 12542248 | 21 | 20140613 | 0 |